The main purpose of this legislation is to improve access to necessary medications for individuals suffering from autoimmune diseases and specific blood disorders under Medicare Part D. The goal is to ensure that these patients can receive the treatments they need without excessive barriers. Key provisions of the legislation require that starting in 2027, Medicare Part D plans must include all drugs prescribed for the treatment of autoimmune diseases, hemophilia, and Von Willebrand disease in their coverage.